Posts by: Alice Melão

News

Basilea Pharmaceutica has dosed its first patient in the expansion part of its Phase 1/2 trial (NCT02895360), which continues to explore the safety and effectiveness of BAL101553, an investigational tumor checkpoint controller, ... Read more

June 29, 2018

AIVITA Advances Phase 2 Clinical Trial for Ovarian Cancer Vaccine

News

AIVITA Biomedical has begun to randomize patients for a Phase 2 clinical trial assessing its cell-based immunotherapy for the treatment of newly-diagnosed advanced ovarian cancer. Currently recruiting participants at Hoag Memorial Hospital Presbyterian ... Read more

June 18, 2018June 18, 2018

FDA Approves Avastin in Combination with Chemotherapy as Treatment for Advanced Ovarian Cancers

News

The U.S. Food and Drug Administration (FDA) has approved the use of Avastin (bevacizumab) in combination with standard chemotherapy, followed by Avastin alone, as a front-line treatment for advanced ovarian ... Read more

June 8, 2018

Phase 3 Trial Testing Pamiparib as Maintenance Therapy for Ovarian Cancer Recruiting Patients in China

News

BeiGene has started enrollment in its Phase 3 clinical trial evaluating the investigational PARP inhibitor pamiparib (BGB-290) as a maintenance therapy for ovarian cancer patients who are responding to platinum-based chemotherapy. The ... Read more

June 4, 2018

Votrient Maintenance Therapy Fails to Improve Survival in Advanced Ovarian Cancer Patients, Trial Results Show

News

Maintenance treatment with Votrient (pazopanib) does not extend the survival of newly diagnosed advanced ovarian cancer patients whose disease did not worsen after surgery and first-line chemotherapy, according to Phase 3 ... Read more

May 7, 2018

Phase 3 Trial of Mirvetuximab Soravtansine in Ovarian Cancer OK’d to Continue as Planned

News

A Phase 3 trial evaluating ImmunoGen’s mirvetuximab soravtansine (IMGN853) in platinum-resistant ovarian cancer patients is on its way to achieving its objectives, an interim futility analysis shows. As a result, the FORWARD ... Read more

April 6, 2018

Bedside Chart Improves Cancer Patients’ Pain Management, Study Shows

News

A simple bedside chart for assessing and managing pain reduced hospitalized cancer patients’ pain without increasing their use of opioids, a large British study showed. Its findings suggested that systematic ... Read more

April 4, 2018

FATE-NK100 Shows Signs of Tumor Reduction in First Ovarian Cancer Patients in Phase 1 Trial

News

FATE-NK100, a natural killer cell immunotherapy, induced stable disease in one of the first two heavily treated ovarian cancer patients in a Phase 1 trial. No dose-limiting toxicities have been reported so ... Read more

March 28, 2018

EU’s CHMP Supports Rubraca’s Approval for Advanced, Recurrent Ovarian Cancer

News

Rubraca (rucaparib) is a step closer to availability in Europe for ovarian cancer patients with relapsed or progressive disease. The E.U.’s Committee for Medicinal Products for Human Use (CHMP) recently ... Read more

March 26, 2018

Phase 1 Trial Finds TPIV200 Is Safe, Delays Recurrence in Ovarian, Breast Cancer

News

An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete ... Read more